

PARSVNATH MIDC PHARMA SEZ PRIVATE LIMITED
(CIN: U24239MH2008PTC178174)
Balance Sheet as at 31 March, 2018

	Note No.	As at 31 March, 2018 ₹	As at 31 March, 2017 ₹
Assets			
1. Current assets			
i. Financial assets			
a. Cash and bank balances	3	22,068	42,381
ii. Other current assets	4	<u>2,06,00,000</u>	<u>2,06,00,000</u>
		2,06,22,068	2,06,42,381
Total Assets		<u>2,06,22,068</u>	<u>2,06,42,381</u>
Equity and Liabilities			
1. Equity			
i. Equity Share capital	5	4,99,00,000	4,99,00,000
ii. Other Equity	6	<u>(2,92,91,912)</u>	<u>(2,92,67,074)</u>
Total Equity		<u>2,06,08,088</u>	<u>2,06,32,926</u>
2. Liabilities			
Current liabilities			
i. Financial assets			
a. Trade payables	7	13,980	8,955
ii. Provisions	8	<u>-</u>	<u>500</u>
Total liabilities		<u>13,980</u>	<u>9,455</u>
Total Equity and Liabilities		<u>2,06,22,068</u>	<u>2,06,42,381</u>
See accompanying notes forming part of the financial statements	1-16		

In terms of our report attached.

For ANUJ & ASSOCIATES

Chartered Accountants

ANUJ JAIN
Partner
Membership No. 87831

Place: Delhi
Date: 10.05.2018

For and on behalf of Board of Directors


Vivek Garg
Director
DIN: 01832495


Yogesh Jain
Director
DIN: 00088662

PARSVNATH MIDC PHARMA SEZ PRIVATE LIMITED
(CIN: U24239MH2008PTC178174)
Statement of Profit and Loss for the year ended 31 March, 2018

	Note No.	Year ended 31 March, 2018 ₹	Year ended 31 March, 2017 ₹
1. Other income	9	-	12,500
Total Revenue		-	12,500
2. Expenses			
Other expenses	10	24,518	9,748
Total Expenses		24,518	9,748
3. Profit before tax (1-2)		(24,518)	2,752
4. Tax expense			
i. Current tax		-	500
ii. Income tax adjustment of previous year		320	-
		320	500
5. Profit after tax (3-4)		(24,838)	2,252
6. Other comprehensive income		-	-
7. Total comprehensive income for the year (5+6)		(24,838)	2,252
8. Earnings per equity share [nominal value of share ₹ 10 each]	11		
(a) Basic (in Rs.)		(0.00)	0.00
(b) Diluted (in Rs.)		(0.00)	0.00

See accompanying notes forming part of the financial statements

1-16

In terms of our report attached.

For ANUJ & ASSOCIATES

Chartered Accountants



ANUJ JAIN

Partner

Membership No. 87831

For and on behalf of Board of Directors


Vivek Garg
 Director
 DIN:01832495


Yogesh Jain
 Director
 DIN:00088662

Place: Delhi

Date:10.05.2018

PARSVNATH MIDC PHARMA SEZ PRIVATE LIMITED
(CIN: U24239MH2008PTC178174)
Statement of Changes in Equity for the year ended 31 March,2018

A Equity Share Capital

Particulars	No of shares	₹
Equity shares of ₹ 10 each issued,subscribed and fully paid		
Balance as at 1 April, 2017	49,90,000	4,99,00,000
Changes in equity share capital during the year	-	-
Balance as at 31 March, 2018	<u>49,90,000</u>	<u>4,99,00,000</u>

B Other Equity

Reserves & Surplus

Particulars	Retained earnings	Total
Balance as at 1 April, 2017	(2,92,67,074)	(2,92,67,074)
Profit for the year	(24,838)	(24,838)
Other comprehensive income for the year	-	-
Balance as at 31 March, 2018	<u>(2,92,91,912)</u>	<u>(2,92,91,912)</u>

See accompanying notes forming part of the financial statements

In terms of our report attached

For Anuj & Associates
Chartered Accountants

Anuj Jain
Partner
Membership No. 087831

Place: Delhi
Date:10.05.2018

For and on behalf of Board of Directors


Vivek Garg
Director
DIN:01832495


Yogesh Jain
Director
DIN:00088662

PARSVNATH MIDC PHARMA SEZ PRIVATE LIMITED
(CIN: U24239MH2008PTC178174)

Cash Flow Statement for the year ended 31 March 2018

	Year ended 31 March, 2018	Year ended 31 March, 2017
	₹	₹
A CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before tax	(24,838)	2,752
	(24,838)	2,752
Adjustments for :		
Trade Payables	5,025	(5,970)
Cash generated from/(used in) operations	(19,813)	(3,218)
Direct taxes paid/deducted at source	500	-
Net cash from/(used in) operating activities	(20,313)	(3,218)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Net cash from/(used in) investing activities	-	-
C. CASH FLOW FROM FINANCING ACTIVITIES		
Net cash from/(used in) financing activities	-	-
D Net increase/ (decrease) in cash and cash equivalents (A+B+C)	(20,313)	(3,218)
E Cash and cash equivalents as at the beginning of the year	42,381	45,599
F Cash and cash equivalents as at the end of the year	22,068	42,381

- 1) The statement of cash flow has been prepared under the indirect method as set out in Ind AS 7 on statements of cash flow.
2) Figures in brackets indicate cash outflow.

See accompanying notes forming part of the financial statements

In terms of our report attached.

For ANUJ & ASSOCIATES

Chartered Accountants


ANUJ JAIN
Partner
Membership No. 87831



For and on behalf of Board of Directors


Vivek Garg
Director
DIN:01832495


Yogesh Jain
Director
DIN:00088662

Place: Delhi
Date:10.05.2018

1 Corporate Information

Parsvnath MIDC Pharma SEZ Private Limited was a Joint Venture between Parsvnath Infra Limited and Maharashtra Industrial Development Corporation till 28.03.2011 and with effect from 29.03.2011, it became a subsidiary of Parsvnath Infra Limited. It has been set up to carry on the activity of establishing, developing, maintaining and operating Special Economic Zones in the areas of pharmaceuticals, drugs and other related areas.

2 Significant Accounting Policies :

2.1 Statement of compliance

The financial statements have been prepared in accordance with the Indian Accounting Standards as notified by Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

The financial statements are presented in Indian Rupee, except when otherwise stated.

2.2 Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle
- Held primarily for the purpose of trading
- Expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

2.3 Basis of preparation and presentation

The financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

2.4 Use of estimates

The preparation of these financial statements in conformity with the recognition and measurement principles of Ind AS requires the management of the Company to make estimates and assumptions that affect the reported balances of assets and liabilities, disclosures relating to contingent liabilities as at the date of the financial statements and the reported amounts of income and expense for the periods presented.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and future periods are affected.

2.5 Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made.

2.6 Taxation

Income tax expense represents the current tax. Current tax is the amount of tax payable as determined in accordance with the provisions of the Income Tax Act, 1961.



2.7 Financial Instruments

A. Initial recognition

Financial assets and financial liabilities are recognised when a Company entity becomes a party to the contractual provisions of the instruments.

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognised immediately in profit or loss.

Cash and cash equivalents

The Company considers all highly liquid financial instruments, which are readily convertible into known amounts of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase, to be cash equivalents. Cash and cash equivalents consist of balances with banks which are unrestricted for withdrawal and usage.

B. Subsequent measurement

I. Non-derivative financial instruments

a. Financial assets carried at amortised cost

Financial assets are subsequently measured at amortised cost if these financial assets are held within a business whose objective is to hold these assets in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

b. Financial assets at fair value through other comprehensive income

Financial assets are measured at fair value through other comprehensive income if these financial assets are held within a business whose objective is achieved by both collecting contractual cash flows that give rise on specified dates to solely payments of principal and interest on the principal amount outstanding and by selling financial assets.

c. Financial assets at fair value through profit or loss

Financial assets are measured at fair value through profit or loss unless it is measured at amortised cost or at fair value through other comprehensive income on initial recognition. The transaction costs directly attributable to the acquisition of financial assets and liabilities at fair value through profit or loss are immediately recognised in profit or loss.

d. Financial liabilities

Financial liabilities are subsequently carried at amortized cost using the effective interest method, except for contingent consideration recognized in a business combination which is subsequently measured at fair value through profit and loss. For trade and other payables maturing within one year from the Balance Sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

II. Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issuance of new ordinary shares and share options are recognised as a deduction from equity, net of any tax effects.

2.8 Operating Cycle

Based on the nature of products/activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current or non current.



PARSVNATH MIDC PHARMA SEZ PRIVATE LIMITED
(CIN: U24239MH2008PTC178174)
Notes forming part of the financial statements

	<u>As at</u> <u>31 March, 2018</u> ₹	<u>As at</u> <u>31 March, 2017</u> ₹
Note 3: Cash and cash equivalents		
a. Cash in hand	12,079	15,936
b. Balance with banks	9,989	26,445
	<u>22,068</u>	<u>42,381</u>
Note 4: Other assets		
Current		
Advance for land purchase to related parties	<u>2,06,00,000</u>	<u>2,06,00,000</u>



A handwritten signature in black ink, appearing to be a stylized 'S' or similar character.

A handwritten signature in blue ink, appearing to be "S. Parash" or similar.

PARSVNATH MIDC PHARMA SEZ PRIVATE LIMITED
(CIN: U24239MH2008PTC178174)

Notes forming part of the financial statements

	As at 31 March, 2018		As at 31 March, 2017	
	Number	₹	Number	₹
Note 5: Equity Share capital				
i. Authorised				
Equity shares of ₹ 10 each	50,00,000	5,00,00,000	50,00,000	5,00,00,000
	50,00,000	5,00,00,000	50,00,000	5,00,00,000
ii. Issued, subscribed and fully paid-up shares				
Equity Shares of ₹ 10 each fully paid	49,90,000	4,99,00,000	49,90,000	4,99,00,000
	49,90,000	4,99,00,000	49,90,000	4,99,00,000
(a) Reconciliation of number of shares outstanding				
i. Shares outstanding at the beginning of the year	49,90,000	4,99,00,000	49,90,000	4,99,00,000
ii. Add: Shares issued during the period	-	-	-	-
iii. Shares outstanding at the end of the year	49,90,000	4,99,00,000	49,90,000	4,99,00,000
(b) Terms/rights attached to equity shares				
i. Each equity holder of each class is entiteled to one vote per share.				
(c) Details of shares held by the holding company, its subsidiaries and associates				
			As at	As at
			31 March, 2018	31 March, 2017
			No of shares	No of shares
Parsvnath Infra Limited			49,90,000	49,90,000
(d) Details of shares held by each shareholders holding more than 5% shares				
	As at 31 March, 2018		As at 31 March, 2017	
	Number of shares held	% holding of equity shares	Number of shares held	% holding of equity shares
Equity shares of ₹ 10 each fully paid				
Parsvnath Infra Limited	49,90,000	100.00%	49,90,000	100.00%



[Handwritten signature]

[Handwritten signature]

PARSVNATH MIDC PHARMA SEZ PRIVATE LIMITED
(CIN: U24239MH2008PTC178174)
Notes forming part of the financial statements

	<u>As at</u> <u>31 March, 2018</u> ₹	<u>As at</u> <u>31 March, 2017</u> ₹
--	--	--

Note 6: Other Equity

a. Reserves & Surplus

i. Retained earnings		
Opening Balance	(2,92,67,074)	(2,92,69,326)
Add: Profit/(Loss)for the year	(24,838)	2,252
Closing balance	<u>(2,92,91,912)</u>	<u>(2,92,67,074)</u>

Note 7: Trade payables

Trade Payables	<u>13,980</u>	<u>8,955</u>
----------------	---------------	--------------

As per the information available with the Company, sundry creditors do not include any amount due to Micro, Medium and Small Enterprises as defined under "Micro, Small and Medium Enterprises Developments Act, 2006 (MSMED Act, 2006) and no interest has been paid or payable in terms of MSMED Act, 2006.

Note 8: Provisions

Provision for Tax	<u>-</u>	<u>500</u>
-------------------	----------	------------



[Handwritten signature]

[Handwritten signature]

PARSVNATH MIDC PHARMA SEZ PRIVATE LIMITED
(CIN: U24239MH2008PTC178174)
Notes forming part of the financial statements

	Year ended 31 March, 2018	Year ended 31 March, 2017
	₹	₹
Note 9: Revenue from operations		
i. Other operating income	-	12,500

Note 10: Other expenses

i. Legal and professional charges	10,717	1,400
ii. Payment to auditors (see note 'i' below)	7,080	6,900
iii. Fees & Taxes	6,026	1,228
iv. Bank charges	695	-
v. Other expenses	-	220
	24,518	9,748

Note 'i'
Payment to auditors

(a) Statutory audit fees	7,080	6,900
--------------------------	-------	-------

Note 11: Earnings per share

i. Net profit for calculation of basic and diluted earnings per share	(24,838)	2,252
ii. Weighted average number of equity shares outstanding during the year	49,90,000	49,90,000
iii. Basic and diluted earnings per share	(0.00)	0.00
iv. Nominal value of equity shares	10	10



[Handwritten signature]

[Handwritten signature]

PARSVNATH MIDC PHARMA SEZ PRIVATE LIMITED
Notes forming part of the financial statements

Note 12: Related party disclosures

- i. **List of related parties**
(a) **Ultimate Holding Company**
- Parsvnath Developers limited

(b) **Holding Company**
- Parsvnath Infra Limited
- ii. **Balances outstanding/transactions with related parties**

	Parsvnath Developers Ltd.
	₹
(a) Transactions during the year	NIL
(b) Balances at year-end	
Advance paid for land purchase	2,06,00,000 (2,06,00,000)

- Figures in brackets represents figures as at and for the year ended 31.03.2017.

Note 13 :Segment reporting

The Company operates in single business and geographical segment, therefore the additional disclosure as required by Ind AS 108 " Operating Segment" have not been provided in the financial statements.

Note 14:Events after the reporting period

There are no event observed after the reported period which have an impact on the company's operations.

Note 15 :Previous year figures

Previous year figures have been regrouped /reclassified wherever necessary to correspond with the classification/disclosure as at 31.03.2018.

Note 16:Approval of financial statements

The financial statements were approved for issue by Board of Directors on 10 May,2018



For and on behalf of Board of Directors


Vivek Garg
Director
DIN:01832495


Yogesh Jain
Director
DIN:00088662

Place: Delhi
Date:10.05.2018